Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 30Cyclophosphamide 18fludarabine phosphate 14Filgrastim 12Mycophenolic Acid 11Antilymphocyte Serum 11Cyclosporine 10Whole-Body Irradiation 9Bortezomib 9Tacrolimus 8Radiotherapy 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 6Lenalidomide 6Cord Blood Stem Cell Transplantation 6Busulfan 6Granulocyte Colony-Stimulating Factor 5venetoclax 4tanespimycin 4Polymerase Chain Reaction 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Bendamustine Hydrochloride 4ublituximab 3thymoglobulin 3pembrolizumab 3ibritumomab tiuxetan 3fludarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, B-Cell, Marginal Zone × oprelvekin × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡